haloperidol decanoate
Long-acting injectable antipsychotic • Brands: HALDOL DECANOATE
Last reviewed: 2025-12-30
General information
- Class: Long-acting injectable antipsychotic
- Common US brands: HALDOL DECANOATE
- Long-acting injectable formulation available.
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2025-12-30
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Long-acting injectable formulation of haloperidol (high-potency dopamine D2 antagonist) designed for monthly maintenance dosing in schizophrenia when scheduled injections support adherence.
Metabolism & Half‑life
- Metabolism: CYP3A4, CYP2D6
- Half‑life: Steady-state mean 504 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Long‑acting injectable (LAI)
Monitoring highlights
- —
Sources
- HALDOL Decanoate (haloperidol decanoate) injection — Prescribing Information — DailyMed (2025)
- Haloperidol tablets prescribing information — DailyMed (2025)
- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia — American Psychiatric Association (2020)
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis — The Lancet (2013)
- AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsycharmacology — Pharmacopsychiatry (2018)